We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.
Scrip is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183
Astellas licenses GI candidate to new Drais virtual company Seldar
07 May 2013
Executive Summary
In a deal structured similarly to one formed between the firms two months ago, Astellas Pharma Inc. and Drais Pharmaceuticals Inc. will ally in the development and commercialization of Astellas’ Phase I bombesin BB2 receptor antagonist ASP7147 for irritable bowel syndrome with diarrhea.
Deal Industry
Biotechnology
Pharmaceuticals
Deal Status
Final
Deal Type
Alliance
R&D and Marketing (Licensing)
Reverse Licensing
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?